138 related articles for article (PubMed ID: 22873092)
1. Chemotherapy-related hypersensitivity reaction in Japanese patients with gynecologic malignancy.
Kitada K; Hashiguchi Y; Fukuda T; Yoshida H; Ichimura T; Matsumoto Y; Yasui T; Sumi T; Ishiko O
Eur J Gynaecol Oncol; 2012; 33(3):252-4. PubMed ID: 22873092
[TBL] [Abstract][Full Text] [Related]
2. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies.
Michikami H; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
J Obstet Gynaecol Res; 2013 Jan; 39(1):330-5. PubMed ID: 22640034
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
6. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
[TBL] [Abstract][Full Text] [Related]
7. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Markman M; Zanotti K; Kulp B; Peterson G; Markman M
Gynecol Oncol; 2003 Jun; 89(3):514-6. PubMed ID: 12798720
[TBL] [Abstract][Full Text] [Related]
8. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
9. Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin.
Chikazawa K; Netsu S; Imai K; Ishiguro A; Kimura A; Wang L; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2020 Jul; 59(4):546-550. PubMed ID: 32653127
[TBL] [Abstract][Full Text] [Related]
10. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
11. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.
Kolomeyevskaya NV; Lele SB; Miller A; Riebandt GC; Blum BL; Odunsi KO; Frederick PJ
Int J Gynecol Cancer; 2015 Jan; 25(1):42-8. PubMed ID: 25356535
[TBL] [Abstract][Full Text] [Related]
13. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
14. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer.
Abe A; Ikawa H; Ikawa S
J Med Invest; 2010 Feb; 57(1-2):163-7. PubMed ID: 20299757
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel.
Brightwell R; Handel E ; Eng K; Grzankowski K; Frederick P; Odunsi K; Lele S
Eur J Gynaecol Oncol; 2016; 37(6):800-802. PubMed ID: 29943924
[TBL] [Abstract][Full Text] [Related]
16. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
Rose PG; Fusco N; Smrekar M; Mossbruger K; Rodriguez M
Gynecol Oncol; 2003 Jun; 89(3):429-33. PubMed ID: 12798707
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
18. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
